TAI LCx

Drug Profile

TAI LCx

Alternative Names: TAI-LCx; Turmeric anti-inflammatory - lipophilic compound x

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arizona
  • Developer Botanisol
  • Class Small molecules
  • Mechanism of Action Prostaglandin modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 23 Oct 2015 Washington State University and Botanisol collaborate to co-develop TAI LCx for Inflammation
  • 15 Oct 2015 TAI LCx is licensed to Botanisol
  • 15 Oct 2015 Botanisol receives Small Business Technology Transfer, program (STTR) grant from the National Institutes of Health and National Center for Complementary and Integrative Health for TAI LCx development in Inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top